MedPath

Comparative study of safety and efficacy of ferric carboxymaltose and iron sucrose in wome

Phase 4
Completed
Conditions
Treatment of iron deficiency anemia in women with different comorbidities
Haematological Disorders
Iron deficiency anaemia, unspecified
Registration Number
ISRCTN14484575
Lead Sponsor
niversity of Kashmir
Brief Summary

2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29304848

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
200
Inclusion Criteria

All patients diagnosed with IDA admitted/or present for consultation in the Obstetrics and Gynecology ward of SKIMS Medical College and Hospital, Bemina, Srinagar were enrolled during the study period

Exclusion Criteria

1. Patients with uncontrolled hypertension
2. Patients with impaired renal function
3. Patients with impaired liver function
4. Patients with heart disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> Measured at baseline, 2 and 4 weeks:<br> 1. The effectiveness and safety of FCM with respect to IS in achieving the target levels of laboratory biomarkers such as Hb, mean corpuscular volume (MCV), serum iron (SI), serum ferritin (SF), transferrin saturation (TS%), total iron binding capacity (TIBC) levels as prescribed under standard guidelines<br> 2. Drug-related problems in patients on FCM or IS<br> 3. The time required to attain normal laboratory biomarker levels<br>
Secondary Outcome Measures
NameTimeMethod
Health-related quality of life (HRQOL), measured using the Medical Outcomes Study Short Form 36 (SF-36) at baseline, 2 and 4 weeks
© Copyright 2025. All Rights Reserved by MedPath